Get the Stockscreener App
1.91
3.50%
-0.09
Mustang Bio Inc stock is traded at $1.91, with a volume of 89,977.
It is down -3.50% in the last 24 hours and down -51.75% over the past month.
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.
See More
Previous Close:
$2.00
Open:
$1.88
24h Volume:
89,977
Relative Volume:
0.31
Market Cap:
$4.93M
Revenue:
-
Net Income/Loss:
$-23.42M
P/E Ratio:
-0.0245
EPS:
-78
Net Cash Flow:
$-16.67M
1W Performance:
-30.58%
1M Performance:
-51.75%
6M Performance:
-86.25%
1Y Performance:
-97.10%
1-Day Range:
$1.80
$1.9895
1-Week Range:
$1.80
$2.85
52-Week Range:
$1.80
$74.50
Mustang Bio Inc Stock (MBIO) Company Profile
Name
Mustang Bio Inc
Sector
Industry
Phone
(781) 652-4500
Address
377 PLANTATION STREET, WORCESTER, NY
Compare MBIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MBIO
Mustang Bio Inc
|
1.952 | 4.93M | 0 | -23.42M | -16.67M | -78.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
488.19 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
689.55 | 75.07B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
634.98 | 37.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.96 | 31.79B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
112.86 | 27.34B | 3.30B | -501.07M | 1.03B | -2.1146 |
Mustang Bio Inc Stock (MBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-18-21 | Initiated | BTIG Research | Buy |
| Oct-02-20 | Initiated | B. Riley FBR | Buy |
| Nov-20-19 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-13-19 | Initiated | H.C. Wainwright | Buy |
| Jun-21-19 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-21-17 | Initiated | Oppenheimer | Outperform |
View All
Mustang Bio Inc Stock (MBIO) Latest News
BRIEF—Mustang Bio sells assets; focuses on MB-109, MB-108 and MB-101 - The Pharma Letter
Mustang Bio (MBIO) Projected to Post Earnings on Monday - Defense World
Mustang Bio stock plunges to 52-week low at $2 - Investing.com
Mustang Bio stock plunges to 52-week low at $2 By Investing.com - Investing.com South Africa
Mustang Bio exits Worcester facility, sells assets to AbbVie By Investing.com - Investing.com Australia
Mustang Bio stock plunges 29% on lease termination news - MSN
Mustang Bio stock plunges 29% on lease termination news (MBIO:NASDAQ) - Seeking Alpha
Mustang Bio exits lease for Massachusetts facility, divests equipment - TipRanks
Mustang Bio to Exit Lease of Worcester, Mass. Manufacturing Facility -February 27, 2025 at 05:49 pm EST - Marketscreener.com
Mustang Bio to Exit Lease of Worcester, Mass. Manufacturing Facility - MarketWatch
Mustang Bio exits Worcester facility, sells assets to AbbVie - Investing.com
Mustang Bio Announces Sale of Fixed Assets and Exit of Facility - The Manila Times
Can Mustang Bio's $3M Financial Boost From Facility Exit Revitalize Its Cancer Therapy Pipeline? - StockTitan
Mustang Bio secures shareholder nod for warrant share issuance By Investing.com - Investing.com South Africa
Mustang Bio secures shareholder nod for warrant share issuance - Investing.com India
Mustang Bio (NASDAQ:MBIO) Stock Quotes, Forecast and News Summary - Benzinga
Mustang Bio stock plunges to 52-week low of $2.6 amid sharp decline - Investing.com Australia
Mustang Bio sells assets and ends lease with AbbVie - MSN
Mustang Bio Sells Assets to AbbVie, Transfers Lease - TipRanks
Mustang Bio stock plunges to 52-week low of $2.6 amid sharp decline By Investing.com - Investing.com South Africa
Mustang Bio regains compliance with Nasdaq minimum bid price requirement - MSN
Mustang Bio, Inc. Regains Compliance with Nasdaq Listing Requirements Following Recent Public Offering - Nasdaq
Mustang Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement - GlobeNewswire
Nasdaq Compliance Alert: Mustang Bio Clears Major Hurdle with $2.5M Equity Milestone - StockTitan
Mustang Bio Closes $8 Million Public Offering - citybiz
Mustang Bio, Inc. Completes Public Offering, Raising Approximately $8 Million for Cancer Cell Therapy Development - Nasdaq
Mustang Bio Announces Closing of $8 Million Public Offering - GlobeNewswire
Mustang Bio (MBIO) Secures Critical $8M Financing Through Strategic Share Offering - StockTitan
Mustang Bio sets terms for $8M public offering - MSN
Mustang Bio sets terms for $8M public offering By Investing.com - Investing.com Canada
Mustang Bio Prices $8 Mln Public Offering - Nasdaq
Mustang Bio Announces Pricing of $8 Million Public Offering - The Manila Times
Mustang Bio Announces Pricing of $8 Million Public Offering - Benzinga
Capital Raise Alert: Mustang Bio Secures Fresh $8M Funding Through Strategic Share & Warrant Offering - StockTitan
Mustang Bio says it needs additional funds to avoid bankruptcy - The Business Journals
Mustang Bio stock plunges to 52-week low of $4 - MSN
Stock market today: VerifyMe -14.42%, PTL -13.23% among biggest losers in early trading - Business Upturn
Mustang Bio Inc. Appoints Michael J. Zelefsky as Director -June 13, 2017 at 04:02 pm EDT - Marketscreener.com
Mustang Bio, Inc. Announces Management Changes -April 24, 2017 at 08:00 am EDT - Marketscreener.com
Mustang Bio, Inc. Appoints Peter Carney as the Interim Chief Accounting Officer -December 12, 2023 at 06:23 am EST - Marketscreener.com
Mustang Bio, Inc. Terminates Exclusive License Agreement with Regents of the University of California - Marketscreener.com
UBriGene Biosciences Inc. completed the acquisition of Worcester manufacturing facility of Mustang Bio, Inc. - Marketscreener.com
Mustang Bio Inc Stock (MBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.23%
1.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):